Martín
Lazaro Quintela
Hospital Clínico San Carlos de Madrid
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Clínico San Carlos de Madrid (9)
2022
-
A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial
European Journal of Cancer, Vol. 175, pp. 110-119
-
Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study)
Lung Cancer, Vol. 173, pp. 83-93
-
Measures to evaluate quality of care in renal cancer: results of a Delphi study in Spain
Clinical and Translational Oncology, Vol. 24, Núm. 3, pp. 495-502
-
SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021)
Clinical and Translational Oncology, Vol. 24, Núm. 4, pp. 635-645
2019
-
Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study
Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2120-2132
2017
-
Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: The necessity of repeated molecular analysis
Translational Lung Cancer Research, Vol. 6, pp. S21-S34
-
Recent advances in genitourinary tumors: A review focused on biology and systemic treatment
Critical Reviews in Oncology/Hematology, Vol. 113, pp. 171-190
2016
-
Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study
BMC Cancer, Vol. 16, Núm. 1
-
Validation of the international metastatic renal-cell carcinoma database consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: The Spanish oncologic genitourinary group (SOGUG) SPAZO study
Annals of Oncology, Vol. 27, Núm. 4, pp. 706-711